| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/09/2005 | EP1505152A1 EXPRESSION SYSTEMS FOR STEM LOOP RNA MOLECULE HAVING RNAi EFFECT |
| 02/09/2005 | EP1505079A2 Heparin with an average molecular weight from 10 to 11,5 kD |
| 02/09/2005 | EP1505075A1 Antibody to human insulin-like growth factor |
| 02/09/2005 | EP1505072A2 Eplerenone crystalline form exhiniting enhanced dissolution rate |
| 02/09/2005 | EP1505069A1 A method of purifying moxidectin through crystallization |
| 02/09/2005 | EP1505068A1 PYRAZOLO (1,5-a) PYRIMIDINE DERIVATIVE AND NAD(P)H OXIDASE INHIBITOR CONTAINING THE SAME |
| 02/09/2005 | EP1505067A1 4,4-disubstituted piperidine derivatives having ccr3 antagonism |
| 02/09/2005 | EP1505066A1 Polymorph of acid 4-[2-[4-[1-(2-ethoxyethyl)-1h-benzimidazole-2-il]-1-piperidinyl]ethyl]-alpha, alpha-dimethyl-benzeneacetic |
| 02/09/2005 | EP1505063A1 Benzimidazole derivatives |
| 02/09/2005 | EP1505062A1 Heterocyclic derivatives and their use as antithrombotic agents |
| 02/09/2005 | EP1505061A1 Compound exhibiting pgd 2 receptor antagonism |
| 02/09/2005 | EP1505049A1 A process for the selective production of dialkyl-polyformals |
| 02/09/2005 | EP1504775A1 A coating for controlled release of a therapeutic agent |
| 02/09/2005 | EP1504764A1 Treatment of liver fibrosis with antagonists of alpha V beta 6 integrin |
| 02/09/2005 | EP1504762A1 Medicine for prevention of and treatment for amyloidosis |
| 02/09/2005 | EP1504761A1 Difructose anhydride-containing composition and use thereof |
| 02/09/2005 | EP1504760A1 Pharmaceutical composition for prophylaxis and therapy of diseases associated with ocular fundus tissue cytopathy |
| 02/09/2005 | EP1504759A1 Oral therapeutic or preventive drugs for pollakiuria and urinary incontinence or oral sleep inducers, containing tropolone derivatives |
| 02/09/2005 | EP1504758A2 Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
| 02/09/2005 | EP1504757A2 Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
| 02/09/2005 | EP1504756A1 Medicament compositions comprising a heterocyclic compound and an anticholinergic |
| 02/09/2005 | EP1504755A1 Lyophilization product |
| 02/09/2005 | EP1504754A1 Gallocatechin gallate-containing composition |
| 02/09/2005 | EP1504124A1 Ldl receptor-related proteins 1 and 2 and treatment of bone or cartilage conditions |
| 02/09/2005 | EP1504118A2 Therapeutic use of selective pde10 inhibitors |
| 02/09/2005 | EP1504040A1 Method for reduction of residual organic solvent in carbomer |
| 02/09/2005 | EP1504034A1 Identification of novel broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies |
| 02/09/2005 | EP1504020A2 Deoxycholic acid derivatives for the treatment of acute dysfunctions of portal and hepatic venous circulation |
| 02/09/2005 | EP1504019A1 Platinum complexes having antitumor activity |
| 02/09/2005 | EP1504014A2 Process for preparation of cyclic prodrugs of pmea and pmpa |
| 02/09/2005 | EP1504010A1 Vitamin-mitomycin conjugates |
| 02/09/2005 | EP1504008A1 7-aminoimidazotriazones |
| 02/09/2005 | EP1504007A1 Imidazo-triazine derivatives as ligands for gaba receptors |
| 02/09/2005 | EP1504006A1 5-ethyl-imidazo[5,1-f][1,2,4]triazin-4(3h)-ones as phosphodiesterase inhibitors |
| 02/09/2005 | EP1504004A2 Substituted pyrazolopyrimidines |
| 02/09/2005 | EP1504003A1 Nitrosated imidazopyridines |
| 02/09/2005 | EP1503998A1 Heteroaryl substituted spirocyclic sufamides for inhibition of gamma secretase |
| 02/09/2005 | EP1503997A1 Cysteine protease inhibitors |
| 02/09/2005 | EP1503996A1 Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors |
| 02/09/2005 | EP1503993A2 Compounds, methods and compositions |
| 02/09/2005 | EP1503992A1 Pyridazin-3(2h)-one derivatives as pde4 inhibitors |
| 02/09/2005 | EP1503991A1 Hexahydro-pyridazine-3-carboxylic acid derivatives, pharmaceutical compositions containing same and preparation methods thereof |
| 02/09/2005 | EP1503989A1 Dopamine receptor modulators as antipsychotic agents |
| 02/09/2005 | EP1503988A2 Fredericamycin derivatives |
| 02/09/2005 | EP1503987A2 Preparation of an anhydrous quinoline-based cetp inhibitor by crystallization |
| 02/09/2005 | EP1503986A2 Compositions and methods for treating heart failure |
| 02/09/2005 | EP1503984A1 8-azaprostaglandin analogs as agents for lowering intraocular pressure |
| 02/09/2005 | EP1503981A2 Substituted tetracycline compounds |
| 02/09/2005 | EP1503806A1 Method for preventing damage to or rejuvenating a cellular blood component using mitochondrial enhancer |
| 02/09/2005 | EP1503803A1 Medicinal formulation in particular for treating herniated invertebral discs |
| 02/09/2005 | EP1503802A2 Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier |
| 02/09/2005 | EP1503800A1 Treatment and prevention of tissue damage |
| 02/09/2005 | EP1503797A1 Injectable pharmaceutical compositions of an anthracenedione derivative with anti-tumoral activity |
| 02/09/2005 | EP1503791A2 Methods of therapy for inducing tolerance |
| 02/09/2005 | EP1503786A2 A method of inhibiting the emigration of cells from the intravascular compartment into tissues |
| 02/09/2005 | EP1503783A1 A combination product comprising an anti-coagulant and anti-arrhythmic oxabispidenes |
| 02/09/2005 | EP1503782A1 A combination product comprising melagatran and an anti-arrhythmic oxabispidenes |
| 02/09/2005 | EP1503779A2 Methods for slowing senescence and treating and preventing diseases associated with senescence |
| 02/09/2005 | EP1503778A2 Formulation of a mixture of free-b-ring flavonoids and flavans as a therapeutic agent |
| 02/09/2005 | EP1503777A1 7-hydroxy chromones as potent antioxidants |
| 02/09/2005 | EP1503775A1 Formulations useful in the treatment of male and female impotence |
| 02/09/2005 | EP1503773A1 Hepatoprotective activity of 2 -p-hydroxybenzoylmussaenosidic acid |
| 02/09/2005 | EP1503769A1 Antibiotic/benzoyl peroxide dispenser |
| 02/09/2005 | EP1503768A1 Inositol pyrophosphates, and methods of use thereof |
| 02/09/2005 | EP1503766A2 Compositions and methods for treating emphysema |
| 02/09/2005 | EP1503765A2 Use of modulators of nicotinic receptors for treatment of cognitive dysfunction |
| 02/09/2005 | EP1503764A1 5-ht4 receptor antagonists for the treatment of heart failure |
| 02/09/2005 | EP1503763A1 Therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions and methods therewith |
| 02/09/2005 | EP1503762A2 Novel crystalline forms of gatifloxacin |
| 02/09/2005 | EP1503761A1 Substituted piperazines as melanocortin receptor ligands |
| 02/09/2005 | EP1503760A1 Camptothecin derivatives and polymeric conjugates thereof |
| 02/09/2005 | EP1503759A2 Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof |
| 02/09/2005 | EP1503758A1 Methods of modulating smooth muscle contractility |
| 02/09/2005 | EP1503757A2 Tyrosine kinase inhibitors |
| 02/09/2005 | EP1503756A1 Epothilone derivative for the treatment of hepatoma and other cancer diseases |
| 02/09/2005 | EP1503755A1 Zonisamide use in obesity and eating disorders |
| 02/09/2005 | EP1503754A1 Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disorders |
| 02/09/2005 | EP1503753A2 A method for inhibiting platelet aggregation |
| 02/09/2005 | EP1503752A1 Use of 8-prenylflavanones for anti-angiogenesis therapy and for fibrinolytic therapy |
| 02/09/2005 | EP1503751A1 Therapeutic methods and compositions involving isoflav-3-ene and isoflavan structures |
| 02/09/2005 | EP1503750A1 Method for the preparation of matairesinol |
| 02/09/2005 | EP1503749A2 Methionine aminopeptidase-2 inhibitors and methods of use thereof |
| 02/09/2005 | EP1503748A1 Drugs for mitigating taxane-induced neurotoxicity |
| 02/09/2005 | EP1503747A1 Diclofenac-based composition for the topical treatment of oropharyngeal cavity disorders |
| 02/09/2005 | EP1503746A1 Pharmaceutical use of cox-2 inhibitors in angiogenesis-mediated ocular disorders |
| 02/09/2005 | EP1503745A2 15625 receptor, a novel g-protein coupled receptor |
| 02/09/2005 | EP1503743A1 Transdermal delivery system with two superimposed adhesive layers having different affinities to the active substance comprised |
| 02/09/2005 | EP1503741A2 Diffusion-controlled dosage form and method of fabrication including three dimensional printing |
| 02/09/2005 | EP1503740A1 Monocompartment osmotic controlled drug delivery system |
| 02/09/2005 | EP1503739A1 Sustained release of guaifenesin combination drugs |
| 02/09/2005 | EP1503737A1 Nanoparticulate nystatin formulations |
| 02/09/2005 | EP1503735A2 A direct cellular energy delivery system |
| 02/09/2005 | EP1503733A1 Oleaginous oral antiparasitic compositions |
| 02/09/2005 | EP1503732A2 Reduced formate poly(alkylene oxides) with secondary amines for reducing impurity formation |
| 02/09/2005 | EP1503731A1 Processes for forming a drug delivery device |
| 02/09/2005 | EP1503730A2 Growth factor delivery system for the healing of wounds and the prevention of inflammation and disease |
| 02/09/2005 | EP1503729A1 Composition and the use thereof as a pharmaceutical or cosmetic formulation for external use |
| 02/09/2005 | EP1503715A2 High-quality lipids and methods for producing by enzymatic liberation from biomass |
| 02/09/2005 | EP1503714A2 Low profile combination device for gastrostomy or jejunostomy applications having anti-granuloma formation characteristics |
| 02/09/2005 | EP1461101A4 Metering valve and pharmaceutical metered dose inhaler and methods thereof |